Syngene International Limited has informed the Exchange regarding appointment of Mr. Peter Bains as an Additional Director, designated as Managing Director & CEO of the Company w.e.f. April 01, 2025.
SYNGENE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts less than Nifty Smallcap 250 and in line with its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Syngene International has appointed Mr. Peter Bains, age 67, as Additional Director designated as Managing Director & Chief Executive Officer, effective April 1, 2025, for a term of 2 years, subject to shareholder approval. Mr. Bains is a familiar face at Syngene — he previously served as CEO for nearly six years from 2010 and led the company through its 2015 IPO. He later returned to the Biocon Group as Independent Director (December 2022) and then became Group CEO of Biocon in September 2023. He also previously held the CEO role at Japan's Sosei Group and had a 23-year career at GlaxoSmithKline in senior commercial and marketing roles.
This is a leadership continuity move — the incoming CEO is a well-known industry veteran with prior Syngene experience and strong global biopharma credentials, which may be viewed positively by investors. Shareholders will need to formally approve the appointment at the next general meeting.